Lipid Biomarkers in Depression: Does Antidepressant Therapy Have an Impact?
Fidelis Christin StuchteyAndrea BlockFrancis OseiPia-Maria WippertPublished in: Healthcare (Basel, Switzerland) (2022)
Studies have revealed mixed results on how antidepressant drugs affect lipid profiles of patients with major depression disorder (MDD). Even less is known about how patients respond to a switch of antidepressant medication with respect to their metabolic profile. For this, effects of a switch in antidepressants medication on lipid markers were studied in MDD patients. 15 participants (females = 86.67%; males = 13.33%; age: 49.45 ± 7.45 years) with MDD and a prescribed switch in their antidepressant medication were recruited at a psychosomatic rehabilitation clinic. Participants were characterized (with questionnaires and blood samples) at admission to the rehabilitation clinic (baseline, T0) and followed up with a blood sample two weeks (T1) later. HDL, LDL, total cholesterol, and triglycerides were determined (T0), and their change analyzed (Wilcoxon test) at follow up (T1). Decrements in HDL ( p = 0.041), LDL ( p < 0.001), and total cholesterol ( p < 0.001) were observed two weeks after a switch in antidepressant medication. Triglycerides showed no difference ( p = 0.699). Overall, LDL, HDL, and total cholesterol are affected by a change in antidepressant drugs in patients with MDD. These observations are of clinical relevance for medical practitioners in the planning and management of treatment strategies for MDD patients.
Keyphrases
- major depressive disorder
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- bipolar disorder
- healthcare
- ejection fraction
- peritoneal dialysis
- prognostic factors
- stem cells
- low density lipoprotein
- depressive symptoms
- patient reported outcomes
- bone marrow
- mesenchymal stem cells
- preterm birth
- general practice
- cell therapy
- high density
- drug induced